Berg Daniela
Hertie Institute of Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Strasse 3, 72076, Tubingen, Germany.
Neurochem Res. 2007 Oct;32(10):1646-54. doi: 10.1007/s11064-007-9346-5. Epub 2007 Apr 28.
A number of investigations have provided evidence for a central role of iron in the pathogenesis of Parkinson's disease (PD). Recently it could be demonstrated that iron related changes of the substantia nigra may be one important factor contributing to the hyperechogenicity typicall visualized by transcranial sonography in idiopathic PD. Moreover, also patients with monogenetically caused PD show this hyperechogenicity, although to a lesser extent. According to numerous findings and experiments it seems plausible that iron also contributes to the pathophysiological cascades in the monogenetic forms of PD. Therefore, it is not only essential to acknowledge the pivotal role of iron for PD, but also to enhance the effort in finding therapeutic strategies to prevent the impact of iron on neurodegenerative processes. Moreover, early detection of subjects at risk is essential for the application of therapeutic strategies at a stage at which neuroprotection is still possible.
多项研究已为铁在帕金森病(PD)发病机制中的核心作用提供了证据。最近可以证明,黑质中铁相关的变化可能是导致特发性帕金森病经颅超声典型显示的高回声性的一个重要因素。此外,单基因遗传性帕金森病患者也表现出这种高回声性,尽管程度较轻。根据众多研究结果和实验,铁似乎也参与了单基因形式帕金森病的病理生理级联反应,这似乎是合理的。因此,不仅要认识到铁对帕金森病的关键作用,还要加大力度寻找治疗策略,以防止铁对神经退行性过程的影响。此外,对高危人群的早期检测对于在神经保护仍然可行的阶段应用治疗策略至关重要。